Anacor Pharmaceuticals Inc (NASDAQ:ANAC) Reports Successful Phase III Trials For Eczema Cream

0
620

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) was happy to announced that its phase III trials for the eczema treatment was a success.

The company’s shares went up due to the good news and thus pointing towards an FDA application. The trial period was a success in two clinical trials carried out on more than 1,500 patients. The treatment marked up significantly against the placebo, thus treating eczema within 29 days. According to the clinical data, the treatment was able to meet its primary endpoint or both trials thus significantly curing many if the patients with the condition.

There was a minimum improvement of about two grades for 32% of the eczema patients. On a different level, roughly half of the patients who had volunteered for the crisaborole treatment, most of them were either cleared or almost despite the time they joined on the scale.

Anacor claims that the side effects of the treatment were insignificant. Only 4.4% of the patients experienced at the point where the cream treatment was applied. 3% of the patients were found to have respiratory infections. None of the patients reported any severe complications or incidences relating to the trial medicine.

Since the trials were a huge success, the company is now planning to apply for an FDA application for Crisaborole. The application is set for the beginning of 2016. Anacor is confident that the FDA approval will not be complex because the trials were a success and will thus provide a compelling argument. The share performance is also a good indicator that the shareholders are also confident about the future of the eczema treatment. The shares went up by roughly 60% on Monday.

The pharmaceutical industry has been very busy especially due to the many acquisitions that have been taking place. Key players such as Sanofi SA (ADR) (NYSE:SNY) have been hard at work trying to perfect their lead drugs. Sanofi and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are currently in phase III trials for an anti-inflammatory drug over which they have partnered up.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.